262 related articles for article (PubMed ID: 31552041)
1. Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.
Park GT; Kwon YW; Lee TW; Kwon SG; Ko HC; Kim MB; Kim JH
Front Immunol; 2019; 10():2095. PubMed ID: 31552041
[TBL] [Abstract][Full Text] [Related]
2. Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.
Park GT; Yoon JW; Yoo SB; Song YC; Song P; Kim HK; Han J; Bae SJ; Ha KT; Mishchenko NP; Fedoreyev SA; Stonik VA; Kim MB; Kim JH
Mar Drugs; 2021 Apr; 19(5):. PubMed ID: 33922418
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
[TBL] [Abstract][Full Text] [Related]
4. WKYMVm-induced activation of formyl peptide receptor 2 stimulates ischemic neovasculogenesis by promoting homing of endothelial colony-forming cells.
Heo SC; Kwon YW; Jang IH; Jeong GO; Yoon JW; Kim CD; Kwon SM; Bae YS; Kim JH
Stem Cells; 2014 Mar; 32(3):779-90. PubMed ID: 24155208
[TBL] [Abstract][Full Text] [Related]
5. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
6. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma.
Yang L; Serada S; Fujimoto M; Terao M; Kotobuki Y; Kitaba S; Matsui S; Kudo A; Naka T; Murota H; Katayama I
PLoS One; 2012; 7(7):e41994. PubMed ID: 22911870
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
8. FPR2/ALX activation reverses LPS-induced vascular hyporeactivity in aorta and increases survival in a pneumosepsis model.
Horewicz VV; Crestani S; de Sordi R; Rezende E; Assreuy J
Eur J Pharmacol; 2015 Jan; 746():267-73. PubMed ID: 25478948
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of cutaneous wound healing by an FPR2-specific peptide agonist WKYMVm.
Kwon YW; Heo SC; Jang IH; Jeong GO; Yoon JW; Mun JH; Kim JH
Wound Repair Regen; 2015; 23(4):575-82. PubMed ID: 25973651
[TBL] [Abstract][Full Text] [Related]
10. Tamibarotene Ameliorates Bleomycin-Induced Dermal Fibrosis by Modulating Phenotypes of Fibroblasts, Endothelial Cells, and Immune Cells.
Toyama T; Asano Y; Akamata K; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Shudo K; Sato S; Kadono T
J Invest Dermatol; 2016 Feb; 136(2):387-398. PubMed ID: 26967475
[TBL] [Abstract][Full Text] [Related]
11. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.
Zhang Z; Wu Y; Wu B; Qi Q; Li H; Lu H; Fan C; Feng C; Zuo J; Niu L; Tang W
Arthritis Res Ther; 2019 Dec; 21(1):290. PubMed ID: 31842999
[TBL] [Abstract][Full Text] [Related]
12. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Ohashi T; Yamamoto T
Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
[TBL] [Abstract][Full Text] [Related]
13. The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model.
Balistreri E; Garcia-Gonzalez E; Selvi E; Akhmetshina A; Palumbo K; Lorenzini S; Maggio R; Lucattelli M; Galeazzi M; Distler JW
Ann Rheum Dis; 2011 Apr; 70(4):695-9. PubMed ID: 21177293
[TBL] [Abstract][Full Text] [Related]
14. The effect of the WKYMVm peptide on promoting mBMSC secretion of exosomes to induce M2 macrophage polarization through the FPR2 pathway.
Zhao W; Hu J; He Q
J Orthop Surg Res; 2021 Mar; 16(1):171. PubMed ID: 33658070
[TBL] [Abstract][Full Text] [Related]
15. TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma.
Mäki-Opas I; Hämäläinen M; Moilanen E; Scotece M
Arthritis Res Ther; 2023 Jan; 25(1):12. PubMed ID: 36698198
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.
Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Miura S; Toyama T; Takahashi T; Ichimura Y; Yoshizaki A; Trojanowska M; Sato S
J Invest Dermatol; 2017 Mar; 137(3):631-640. PubMed ID: 27777101
[TBL] [Abstract][Full Text] [Related]
17. Antifibrogenic effects of C-C chemokine receptor type 2 antagonist in a bleomycin-induced scleroderma model.
Ishikawa M; Yamamoto T
Exp Dermatol; 2021 Jan; 30(1):179-184. PubMed ID: 32096250
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.
Castelino FV; Seiders J; Bain G; Brooks SF; King CD; Swaney JS; Lorrain DS; Chun J; Luster AD; Tager AM
Arthritis Rheum; 2011 May; 63(5):1405-15. PubMed ID: 21305523
[TBL] [Abstract][Full Text] [Related]
19. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.
Lakos G; Takagawa S; Chen SJ; Ferreira AM; Han G; Masuda K; Wang XJ; DiPietro LA; Varga J
Am J Pathol; 2004 Jul; 165(1):203-17. PubMed ID: 15215176
[TBL] [Abstract][Full Text] [Related]
20. Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice.
Szabó A; Czirják L; Sándor Z; Helyes Z; László T; Elekes K; Czömpöly T; Starr A; Brain S; Szolcsányi J; Pintér E
Arthritis Rheum; 2008 Jan; 58(1):292-301. PubMed ID: 18163477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
